Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Other financing activities (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Other financing activities for 3 consecutive years, with $4.4 million as the latest value for Q2 2025.

  • On a quarterly basis, Other financing activities changed N/A to $4.4 million in Q2 2025 year-over-year; TTM through Sep 2025 was -$5.7 million, a N/A change, with the full-year FY2024 number at -$5.3 million, changed N/A from a year prior.
  • Other financing activities was $4.4 million for Q2 2025 at Centessa Pharmaceuticals, up from -$4.8 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $4.4 million in Q2 2025 to a low of -$5.3 million in Q4 2024.
  • A 3-year average of -$1.5 million and a median of -$2.5 million in 2022 define the central range for Other financing activities.